Who are Alumis's investors?

Alumis's investors include Foresite Capital, General Atlantic, HBM Healthcare Investments, HBM Partners, Nextech Invest, OrbiMed, Samsara BioCapital, SR One Capital Management and 3 more.

How much funding has Alumis raised?

Alumis has disclosed $345.1M raised across 1 round.

Where is Alumis headquartered?

Alumis is headquartered in South San Francisco, US.

Alumis

NASDAQ: ALMS

South San Francisco, US · Founded 2021 · 262 employees on LinkedIn · 11 known investors

Find your way into Alumis

Paths you didn't know you had: your email and LinkedIn already hold routes to the Alumis team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.

AI & Machine Learning Biotech Digital Health Healthtech Longevity

Founders & leadership

Martin BablerPresident, Chief Executive Officer and Chairman of the BoardHe has served on the boards of Prelude Therapeutics since 2021, 89bio from 2024 to 2025, and as chairman of the board of Sardona Therapeutics from 2021 to 2025. He has also been a co-owner of Paradigm Ranch Management LLC since 2008.

Mark BradleyChief Development Officer

Kolbot BySVP, Head of Technical Operations

Jack DanilkowiczChief Commercial OfficerChief Commercial Officer at Alumis, a clinical-stage biopharmaceutical company. Jack has experience in sales, marketing, operations, and business development.

Jörn DrappaChief Medical OfficerJörn Drappa is Chief Medical Officer of Alumis, a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. He is a board-certified internist and rheumatologist with 30 years of research and clinical experience, including 19 years in pharmaceutical and biotech industry roles involving small and large molecule development across phases I–III in asthma, COPD, systemic lupus erythematosus, dermatological, cardiovascular, and orphan disease programs.

David M GoldsteinChief Scientific Officer

Grace HaltehSVP, Head of Quality and Regulatory

Roy HardimanChief Business and Strategy Officer

Claire LangrishSVP, Head of Immunology and Translational ScienceClaire Langrish is an immunologist and drug discoverer serving as SVP and Head of Immunology and Translational Science at Alumis, where she leads preclinical and clinical translation efforts in immunology. Her research has focused on immune-mediated disease mechanisms and drug development.

Sanam PangaliChief Legal Officer and Corporate Secretary

John SchroerChief Financial Officer

Investors · 11

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us

General Atlanticlisted by General AtlanticNew York · $10M – $1B

How we know: generalatlantic.com · Not right? Tell us

HBM Healthcare Investmentslisted by HBM Healthcare InvestmentsZug

How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us

HBM Partnerslisted by HBM PartnersZug · $5M – $50M

How we know: HBM Partners's portfolio page · Not right? Tell us

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · the S-1 prospectus · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Francisco

How we know: a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Westlake Village BioPartnerslisted by Westlake Village BioPartnersLos Angeles · $100K – $5M

How we know: Westlake Village BioPartners's portfolio page · the VCSheet dataset · Not right? Tell us

venBio Global StrategicinferredSan Francisco

How we know: board seat on SEC Form D · Not right? Tell us

Funding

SEC filings, press & company announcements

$345.1M disclosed across 1 round · 2026

$345.1Mpublic offeringJan 2026 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events

$830.5Mvaluation at IPOJun 2024 · $16.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 3

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Companies working in the same space as Alumis.

Frequently asked questions

What does Alumis do?: Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Who are Alumis's investors?: Alumis's investors include Foresite Capital, General Atlantic, HBM Healthcare Investments, HBM Partners, Nextech Invest, OrbiMed, Samsara BioCapital, SR One Capital Management and 3 more.
How much funding has Alumis raised?: Alumis has disclosed $345.1M raised across 1 round.
Where is Alumis headquartered?: Alumis is headquartered in South San Francisco, US.